Dutch DRUP Trial Demonstrates Significant Potential for Off-Label Cancer Drug Use in Advanced Patients
核心洞察
The Dutch multicenter DRUP trial, involving over 1,600 patients with advanced cancers, showed that approximately one-third of patients responded to off-label targeted therapies or achieved stable disease for at least four months.
Sixty-seven exceptional responders across different molecular subgroups demonstrated complete response or remained progression-free for at least two years, highlighting the potential for durable benefit in heavily pretreated patients.
The study achieved full national reimbursement for a new treatment option for patients with MSI tumors (搜索), demonstrating how systematic evaluation can expand patient access to medicines.
The largest published prospective evaluation of off-label targeted cancer therapies (搜索) has demonstrated that existing drugs could benefit significantly more patients than currently treated, according to results from the Dutch multicenter DRUP trial published in Nature. The decade-long study included over 1,600 patients with advanced cancers who had exhausted standard treatment options.
Trial Design and Patient Outcomes
The pan-cancer (搜索) DRUP trial provided off-label treatment opportunities by matching patients to existing drugs registered for other cancer types where their specific DNA profiles are more commonly found. This personalized approach yielded encouraging results across multiple metrics.
Approximately one-third of participants responded to treatment or achieved stable disease for at least four months. The overall survival reached 8 months, though roughly one in four patients experienced serious side effects. These outcomes represent meaningful clinical benefit for a patient population with limited therapeutic options.
Exceptional Responders Highlight Treatment Potential
Perhaps most significantly, 67 exceptional responders emerged across different molecular subgroups, demonstrating either complete response or remaining progression-free for at least two years. This finding illustrates the potential of targeted drugs to deliver profound and durable benefit, even in heavily pretreated, difficult-to-treat, or rare cancers (搜索).
"Our findings underscore the fact that effective off-label use is possible, but should only be done within clinical trial settings," stated the research team in their published results.
Clinical Framework and Access Implications
Principal investigator Emile Voest from the Netherlands Cancer Institute (搜索) and Oncode Institute (搜索) emphasized the importance of systematic evaluation. "Off-label anticancer drugs (搜索) should only be prescribed within frameworks that systematically evaluate efficacy and toxicity," Voest explained. "Oncologists often treat patients with off-label treatments outside trial settings. This involves significant risks of toxicity, costs and uneven access."
The trial's systematic approach has already yielded concrete benefits for patient access. One DRUP expansion cohort generated sufficient evidence to achieve full national reimbursement for a new treatment option for patients with MSI tumors (搜索), demonstrating how rigorous data collection can lead to expanded treatment access.
Expanding European Network
The DRUP trial has catalyzed the development of a growing European network of investigator-initiated trials with similar protocols. This network promises to build an invaluable source of evidence, particularly for patients with rare cancers (搜索) who face limited treatment options and trial opportunities.
Earlier analysis of DRUP data showed that comprehensive molecular testing in patients with rare cancers (搜索) may identify treatment opportunities and clinical benefit similar to patients with common cancers, suggesting broad applicability of this approach.
Research Leadership and Support
The study was led by principal investigators Emile Voest from the Netherlands Cancer Institute (搜索), Henk Verheul from Erasmus MC Cancer Institute (搜索), and Hans Gelderblom from LUMC (搜索). The research received financial support from KWF Dutch Cancer Society (搜索) and Stelvio for Live, with the Emile Voest group operating as part of the Oncode Institute (搜索).
The findings represent a significant step toward more personalized cancer (搜索) treatment approaches while establishing the critical importance of conducting off-label drug use within structured clinical trial frameworks to ensure both patient safety and systematic evidence generation.